National Institutes of Health logo

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

National Institutes of Health

Federal

Funding Amount

Up to $300K

Deadline

Forecast — expected June 4, 2027

Forecast by the agency; not yet open

Number of Awards

14

Grant Type

Federal

Deadline history & next window

Cycle
Not stated
Next expected
June 4, 2027
Tracked since
September 2026

Forecast: expected to post January 15, 2027; applications expected due June 4, 2027.

Source: Grants.gov forecast for this opportunity.

Can we apply?

Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.

Eligible organizations

  • Small businesses
  • Nonprofits without 501(c)(3) status
  • Private colleges & universities
  • Tribal organizations
  • School districts
  • For-profit businesses
  • Public & Indian housing authorities
  • State governments

Geography

  • Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Overview

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development, enhancements, optimizations, and rigorous technical validation to encourage adoption by the research community.

Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the clinical target or biological question being pursued are not appropriate for this solicitation.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Full eligibility text

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Focus Areas & Funding Uses

Fields of Work

  • Health

Related Grants

Open grants from this funder and similar programs

Your AI grants department

Ready to apply for Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)?

Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.

You found Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed). Now let's win it.

Start writing